Table 2.
Analysis of the included clinical trials with non-statin anti-hyperlipidaemic drugs in China from 1989 to 2019
| The clinical trials with non-statin anti-hyperlipidaemic drugs | Single-arm trials | Controlled trials | |||||
| Number of trials | Control group | Experimental group | The patients treated with non-statin lipid-lowering drugs | ||||
| Number of trials | Number of patients | Number of patients | Number of patients | Number of trials | Number of patients | ||
| Fibrates | |||||||
| Fenofibrate | 39 | 2458 | 29 | 1134 | 1274 | 68 | 3732 |
| Gemfibrozil | 10 | 410 | 6 | 259 | 350 | 16 | 760 |
| Bezafibrate | 2 | 50 | 8 | 449 | 481 | 10 | 531 |
| Etofylline clofibrate | 2 | 90 | 2 | 105 | 119 | 4 | 209 |
| Subtotal | 53 | 3008 | 45 | 1947 | 2224 | 98 | 5232 |
| Nicotinic acid and derivatives | |||||||
| Niacin | 1 | 165 | 0 | 0 | 0 | 1 | 165 |
| Acipimox | 7 | 612 | 1 | 60 | 30 | 8 | 642 |
| Subtotal | 8 | 777 | 1 | 60 | 30 | 9 | 807 |
| Others | |||||||
| Probucol | 6 | 466 | 3 | 88 | 95 | 9 | 561 |
| Cholestyramine | 0 | 0 | 1 | 38 | 67 | 1 | 67 |
| Subtotal | 6 | 466 | 4 | 126 | 162 | 10 | 628 |
| Total | 67 | 4251 | 50 | 2133 | 2416 | 117 | 6667 |